TAM
ACRS icon

Tocqueville Asset Management’s Aclaris Therapeutics ACRS Stock Holding History

Tocqueville Asset Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-33,000
Closed -$845K – 804
2016
Q3 		$845K Buy
33,000
+23,000
+230% +$488K 0.01% 531
2016
Q2 		$185K Buy
+10,000
New +$198K ﹤0.01% 797

Other funds holding ACRS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SMV
Sofinnova Management VIII Menlo Park, California $183M AUM 4.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Tocqueville Asset Management's ACRS Position: Q4 2016 in Review

Tocqueville Asset Management sold out of Aclaris Therapeutics (ACRS) in Q4 2016, closing a stake of 33,000 shares — an estimated $845K sold.

Tocqueville Asset Management first reported a position in ACRS in Q2 2016 and held it in 2 quarters. The position peaked at $845K in Q3 2016. 100 funds tracked by Wall St. Rank hold ACRS as of Q4 2016.

  • Tocqueville Asset Management reported no remaining Aclaris Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Tocqueville Asset Management sold 33,000 Aclaris Therapeutics shares in Q4 2016, an estimated $845K.
  • Tocqueville Asset Management first reported a position in Aclaris Therapeutics in Q2 2016 and held it in 2 quarters.
  • Tocqueville Asset Management's Aclaris Therapeutics position peaked at $845K in Q3 2016.
  • 100 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2016.

Based on Tocqueville Asset Management's 13F filing for Q4 2016, filed 30 Jan 2017.